Conditions: Hepatitis C, Chronic
Keywords: thrombopoietin hepatitis C ribavirin platelets Hepatitis C-related thrombocytopenia peginterferon alfa-2a
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 687
Healthy volunteers: no

Brief summary:
The purpose of this study is to assess the ability of eltrombopag to maintain a platelet count sufficient to facilitate initiation of antiviral therapy, to minimise antiviral therapy dose reductions and to avoid permanent discontinuation of antiviral therapy. The clinical benefit of eltrombopag will be measured by the proportion of subjects who are able to achieve a Sustained Virological Response (SVR).

Detailed description:

Arms:

Interventions: intervention 1: eltrombopag intervention 2: placebo
Intervention descriptions: intervention 1: 25, 50, 75, 100 mg tablets taken once daily orally intervention 2: matched placebo taken once daily orally

Protocol document: